Pharma Leader Series: Top Stem Cell Companies Report 2016-2026

Apr 22, 2016, 09:00 ET from Visiongain

LONDON, April 22, 2016 /PRNewswire/ --

Market Analysis and Leading Players in the United States, Europe, Israel and Asia

Leading Stem Cell Companies - Discover What Their Futures Hold, Benefiting Your Reputation for Commercial Insight

Who are the leading stem cell developers and producers? And what are their sales outlooks? Visiongain's updated report shows you their activities and potentials from 2016. There you discover therapies, results, trends in research and development, opportunities and revenue forecasts.

That way you explore data and discussions on cellular technologies transforming human medicine. Our study analyses 25 leading companies in the US, Europe, Israel and Asia-Pacific. There you hear how stem cell producers can progress and gain. Discover their potentials and see what the future holds.

Please read on, then, to scan those organisations and find what revenue that fast-growing and potentially large market could generate in future. See what is possible.

Forecasts and other data to benefit your authority on stem cell biotechnology
In our study you find profiles of 25 prominent stem cell companies and analyses of their industry. You explore sales results, R&D and revenue forecasting. Explore, from 2016, those firms' capabilities, portfolios and commercial prospects.

In our updated report you gain 55 tables, 24 charts and two interviews with that industry. You see our discussions with authorities from Mesoblast and Gamida Cell.

With our study you could help your research, analyses and decisions, also saving time. And see how you could benefit your reputation for commercial insight.

Stay ahead, then, for knowledge on that vast, rising industry. The following sections explain how our new investigation benefits your work.

United States (US) - assess leading organisations, seeing what is possible
First our study gives you discussions, analyses and commercial outlooks for 11 US-based stem cell companies:

• Osiris Therapeutics

To see a report overview please email Sara Peerun on

• Caladrius Biosciences
• Orthofix
• NuVasive
• AlloSource
• RTI Surgical
• Vericel Corporation
• U.S. Stem Cell, Inc.
• Neuralstem
• Astellas/Ocata Therapeutics
• Athersys

There you hear what the future holds for those cellular biology companies, including regulations, research trends and some revenue predictions.

Our study then analyses Asian organisations, explaining that region's potential.

Stem cell specialists based in the Asia Pacific region - what developments possible?
You also discover commercial outlooks for six top researchers, developers and producers of stem cells in the Asia Pacific region:
• Mesoblast
• Reliance Life Sciences
• Anterogen
• Pharmicell
• Stempeutics.

Our analyses show possibilities for advancing technology and raising business performance, assessing where future sales expansion is possible. Explore regulations and see how companies progress, assessing revenue potentials.

The report then analyses Europe and Israel, showing those countries' activities and potentials.

Companies based in Europe and Israel - what successes can they achieve?
Our analysis also shows you progress and prospects for eight European and Israeli companies:
• TiGenix
• Celyad
• Apceth
• ReNeuron
• Gamida Cell
• Cell Cure Neurosciences
• Pluristem Therapeutics
• BrainStorm Cell Therapeutics.

Many opportunities arise in that industry, with high, expanding revenues possible from this decade. In our study you also explore clinical testing and plans for launching products.

Predictions for the worldwide stem cells market - see that industry's sales potential
Our report also forecasts sales to 2026 for the overall world stem cells industry. There you find revenues reaching $17.8bn in 2020, with high growth to 2026.

In our study you also gain revenue forecasting to 2026 for these products:
• Trinity Elite and Trinity Evolution
• Osteocel Plus
• MSC-100-IV
• CardioRel
• Hearticellgram-AMI
• Cartistem.

See there how applications of stem cells can perform. Find, from 2016, where those organisations can generate high sales. That industry holds vast potential.

With our report you assess how stem cell companies can compete and succeed. See what their future holds and how you can gain.

Technologies and issues shaping that industry and market - what is happening?
Our study explains stem cell technologies and forces influencing that industry and market. There you explore developments and forces, including these:
• Sales potentials of leading stem cell therapies to 2026 - see what is possible
• Embryonic stem cells - potentials in tissue repair and regenerative medicine
• Autologous and allogeneic agents, including T cell therapy
• Advances in treating eye disorders, e.g. age-related macular degeneration (AMD)
• Novel treatments for cancer and other applications - e.g. diabetes and bone re-growth - including progress of clinical trials and product launches.

With that work you assess these influences, too, among others:
• Regulations for that research and its applications - see what countries do
• Umbilical cord blood - applications and approvals for that tissue and cell banking
• Mergers, acquisitions, alliances and venture capital - explore what shapes that industry and affects its future
• Non-therapeutic pharma applications - screening and toxicity studies in drug development.

In our survey you also find interviews with two companies - Mesoblast and Gamida Cell. There gain information to help you stay ahead in knowledge on challenges, progress, potentials and future trends.

See what is possible, then, for that cell-based biotechnology and explore what its future holds.

Ways Pharma Leader Series: Top Stem Cell Companies Report 2016-2026 helps you
In particular, our independent analysis gives you this knowledge to benefit your work:
• Profiles of 25 leading stem cell companies in North America, Europe, Israel and Asia - assess products, R&D, results, strategies, alliances and sales outlooks
• Revenue forecasting to 2026 for that overall world market - discover potential sales, exploring those technologies' commercial prospects
• Forecast revenues to 2026 for leading stem cell products - see how top companies' technologies can compete and succeed
• Opportunities, competition and demands - explore what affects companies, finding what influences sales and shapes organisations' futures
• Interviews with companies in that industry - find what participants say and do, helping you stay ahead in knowledge and benefit your influence.

That report, by visiongain's in-house analysts in the UK, gives knowledge to benefit your work. Its purpose is to help you save time and avoid struggles to find information. You gain analysis to benefit your plans, decisions and presentations.

Data found nowhere else, benefiting your research, analyses and proposals
Our report gives independent analysis. There you get competitive intelligence found only in that work, assessing commercial potentials. Explore what the future holds.

With our analysis you are less likely to fall behind in information or miss opportunity. There see how you could save time and effort. So benefit your plans, decisions and influence now, helping you gain advantages and succeed.

By trying our latest study on stem cells, you explore trends, R&D and sales predictions. You assess the present and future of companies. Avoid missing out on data and discussions to help you stay ahead. So please get our new report here now.

To see a report overview please email Sara Peerun on

To request an exec summary of this report please email Sara Peerun at or call Tel: +44(0)20-7336-6100

Or click on

Organisations Mentioned in the Report 

Aastrom Biosciences (now called Vericel Corporation)

Advanced Cell Technology (now called Ocata Therapeutics)




American Academy of Pediatrics










Auriga Ventures

BaYi Brain Hospital

Benitec Biopharma

Berlin-Brandenburg Center for Regenerative Therapy




Blackstone Medical

Bloodworks Northwest

BrainStorm Cell Therapeutics

Bristol-Myers Squibb

Caladrius Biosciences

California Institute of Regenerative Medicine (CIRM)

California Stem Cell Inc

Cardio3 BioSciences

Carolinas Cord Blood Bank (CCBB)

Casey Eye Institute

Catapult Cell Therapy


Cell Cure Neurosciences






CFDA (China Food and Drug Administration)

CHA Bio & Diostech

Cha General Hospital

Charité - University Medicine Berlin

China's National Health and Family Planning Commission (NHFPC)

Chinese Academy of Sciences

Chinese Ministry of Health

Chinese Ministry of Science and Technology

Chugai Pharmaceutical


CJ CheilJedang

Clal Biotechnologies Industries

ClinImmune Labs

Columbia University

Committee for Advanced Therapies (CAT)

Committee for Medicinal Products for Human Use (CHMP)

Corniche Group

CRISPR Therapeutics

CSCR (Centre for Stem Cell Research)

Cynata Therapeutics

Denali Ventures

Dong-A Pharmaceuticals Co.

Duke University School of Medicine

Editas Medicine

Elbit Imaging

Elbit Medical Technologies

Eli Lilly


European Commission

European Medicines Agency (EMA)

Forbion Capital Partners

Fukushima Global Medical Science Center

Fukushima Medical University

Gamida Cell



Gladstone Institute

Hadasit Bio-Holdings, Ltd (HBL)

Hadassah University Hospital

Harvard Medical School


Hebrew University of Jerusalem

Human Fertilisation and Embryology Authority (HFEA)

Human Stem Cells Institute

ICMR (Indian Council for Medical Research)

IC-SCRT (Institutional Committee for Stem Cell Research)

Indian Department of Biotechnology

Intellia Therapeutics

International Society for Stem Cell Research (ISSCR)


ISCS (Israel Stem Cell Society)

Israel Healthcare Venture

Israel Stem Cell Society

Japanese Health Ministry

Japanese Institute of Biomedical Research

Japanese Ministry of Economy, Trade and Industry (METI)

Japanese NHI (National Health Insurance)

Japanese PMDA (Pharmaceutical and Medical Devices Agency)

JCR Pharmaceuticals

JingYuan Bio

Korean Food and Drug Administration (KFDA)

Korean Ministry of Food and Drug Safety (MFDS)

Korean Ministry of Health and Welfare



Lincoln Park Capital Fund


Mayo Clinic

Medicines and Healthcare Products Regulatory Agency (MHRA)


Medisun International Limited


Merck Millipore


Michigan State University

Monash University

Musculoskeletal Transplant Foundation (MTF)

NAC-SCRT (National Apex Committee for Stem Cell Research and Therapy)

National Institute of Health and Care Excellence (NICE)




New York Blood Center

New York Heart Association

NHFPC (National Health and Family Planning Commission)

NHMRC (National Health and Medical Research Council)



Ocata Therapeutics

OCS (Office of the Chief Scientist)

Octane Biotech Inc

Oregon Health and Science University

OrLife Bio


Osiris Therapeutics


Phase III Medical Inc.

Pluristem Therapeutics

Progenitor Cell Therapy (PCT)

Puget Sound Blood Center


Reliance Group

Reliance Life Sciences



RTI Surgical


Schepens Eye Research Institute

Singapore National Eye Centre

Society for Neuroscience

Society for Stem Cell Research (ISSCR)

SSM Cardinal Glennon Children's Medical Center

St. Louis Cord Blood Bank



Stryker Corporation

Swedish Orphan Biovitrum AB (Sobi)

Tel Aviv University

Teva Pharmaceutical Industries

TGA (Therapeutic Goods Administration)

The Lancet




UK Department of Health and the Medical Research Council

UK Medicines and Healthcare Products Regulatory Agency (MHRA)


United Nations Department of Economic and Social Affairs

United Therapeutics

University College London

University of Colorado Anschutz Medical Campus (AMC)

University of Colorado Cord Blood Bank

University of Kyoto

University of Melbourne

University of Wisconsin Alumni Research Foundation

US Congress

US Department of Defense (DOD)

US Federal Reserve

US Food and Drug Administration (FDA)

US National Academy of Sciences

US National Institute of Health

US Patent and Trademark Office

U.S. Stem Cells Inc.

Vericel Corporation


Woodford Investment Management

Yonsei University

To see a report overview please email Sara Peerun on

SOURCE Visiongain